Amy Arndt, APRN
Primary Care · Lincoln, NENPI 1407843048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 37.4% of the total.
Across 127 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$885
- Novo Nordisk$222
- Gilead$180
- Pfizer$140
- Biohaven Pharmaceuticals, Inc.$134
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$96
- plus $712 from 24 others
What the payments were for
- Food & beverage$2,356100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$125
How this compares
$2,368 in reported general payments places this provider in the 85th percentile of 65 primary care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 75 | $63,177 |
| OzempicSemaglutide | 66 | $62,875 |
| TrulicityDulaglutide | 35 | $42,635 |
| EliquisApixaban | 37 | $23,128 |
| Nurtec OdtRimegepant Sulfate | 11 | $21,446 |
| XareltoRivaroxaban | 17 | $20,710 |
| Emgality PenGalcanezumab-Gnlm | 17 | $12,127 |
| LinzessLinaclotide | 19 | $11,368 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,253 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $10,038 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 32 | $9,932 |
| XyostedTestosterone Enanthate | 13 | $8,511 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,584 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 30 | $6,581 |
| VeozahFezolinetant | 11 | $5,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr | $34 | $73,75599 claims |
| Novo NordiskOzempic | $222 | $62,87566 claims |
| PfizerEliquis, Nurtec Odt | $140 | $44,57448 claims |
| Lilly USA, LLCTrulicity | $68 | $42,63535 claims |
| Johnson & JohnsonXarelto | $20 | $20,71017 claims |
| GSKArexvy, Shingrix | $68 | $16,51262 claims |
| AbbVieLinzess | $885 | $11,36819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $11,25323 claims |
| Astellas Pharma US IncVeozah | $30 | $5,95111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 primary care providers in Nebraska.
Other primary care in Lincoln
- Laurel DubaLincoln$5K
- Jaimie RussellLincoln$1K
- Corrine WaddellLincoln$607
- Amy McCrackenLincoln$532
- Indra SukhramLincoln$358
- Kristin ButterfieldLincoln$269
- Jamie RhoadesLincoln$219
- Taylor NunnenkampLincoln$69
- Brandon AndersonLincoln$68
- Jenna KoppOmaha$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.